1Vanden BH , Engelen M , Rochette F. Antifungal agents of use in animal health chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther, 2003, 26: 5- 29.
2Maenza JR, JC Keruly, RD Moore, et al. Risk factors for fluconazole - resistant candidiasis in human immunodeficiency virus -infected patients. Infect Dis, 1996, 173:219-225.
3Millon L, A Manteaux, G Reboux, et al. Fluconazole - resistant recurrent oral candidiasis in human immunodeficiency virus - positive patients : persistence of Candida albicans strains with the same genotype. Clin Microbiol, 1994, 32:1115-1118.
4Heald AE, GM Cox, WA Schell, et al. Oropharyngeal yeast flora and fluconazole resistance in HIV - infected patients receiving long -term continuous versus intermittent fluconazole therapy. AIDS, 1996. 10:263-268.
5Laguna F, JL Rodriguez - Tudela, JV Martinez - Suarez, et al.Patterns of fluconazole susceptibility in isolates from human immu nodeficiency virusinfected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis, 1997, 24: 124-130.
6Sanguineti A, JK Carmichael, K Campbell. Fluconazole -resistant Candida albicans after long - term suppressive therapy. Arch Intern Med, 1993, 153: 1122- 1124.
7Sobel JD, JA Vazquez. Symptomatic vulvovaginitis due to llucon azole - resistant Candida albieans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis, 1996, 22 726-727.
8Redondo- Lopez V, M Lynch, C Schmitt, et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol, 1990, 76:651-655.
9Rex JH, Rinald MG. Resistance of Candida species to fluconazole. Aruinucrob Agew Chenarer, 1995, 39 (1): 1-6.
10Law D, CB Moore, HM Wardle, et al. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. Antimicrob Chemother, 1994, 34: 659- 668.
二级参考文献115
1Rex J H, Rinald M G. Resistance of Candida species to fluconazole[J]. Antimicrob Agents Chemoter,1995;39(1):1.
2Espinal-ingroff A, Kerkering T M,Goldson P R, et al.Comparison study of broth macrodilution and microdilution antifungal susceptibility tests[J].J Clin Microbiol, 1992 ;30(12)3138.
3Galgiani J N,Reiser J, Brass C,et al. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods [ J]. Antimicrob Agents Chemother, 1987,31(9) : 1342.
4National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts[S].Approved standard. Document M27- A. N27- A.National Committee for clinicalLaboratory Standards, Wayne Pa 1997:24.
5Horsburgh C A, kirkpatrick C H. Long - term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients [J] .Am J Med,1983;74(1) :23.
6Akora M, Akalin H E, Uzum O, et al. Emergence of Candida krusei infections after therapy of oropharyneal candidiasis with fluconazole [J]. Eur J Clin Microbiol Infect Dis. 1991;10(3):598.
7Darouiche R O. Oropharyngeal and esophageal candidiasis in immunocompromisd patients: treatment issues[J]. Clin Infec Dis,1998,26(2) :259.
8Lewis R E, Klepser M E. The changing face of nosocomial candidemia: epdemiology,resistance and drug therapy [ J]. Am J Health Syst Pharm. 1999,56(6) :525.
9Akova M, Akalin H E, Uzun O, et al. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome [ J]. Clin Infect Dis, 1994,18(2) :296.
10Barchiesi D, Colombo A L, McGough D A, et al. In vitro activity of itraconazole against fluconazole- susceptible and resistant Candida albicans isolated from oral cavities of patieat infected with HIV [J]. Antimicrob Agents Chemother, 1994,38(7) : 1530.
